BioDelivery Sciences picks up US rights to opioid-induced constipation drug Symproic

11 April 2019
drugs_pills_tablets_big

Shionogi (TYO: 4507) says it has out-licensed full US commercialization rights for its approved medication, Symproic (naldemedine).

The Japanese firm has granted the rights to the chronic pain specialist BioDelivery Sciences (Nasdaq: BDSI), effective immediately, in return for an upfront cash payment of $20 million, an additional $10 million in six months, as well as quarterly royalty payments.

Symproic is an oral tablet which functions as a peripherally acting mu-opioid receptor antagonist medication. It is approved in the USA to be marketed for certain people with opioid-induced constipation (OIC).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical